Pain Quality Assessment Scale for Epidermolysis Bullosa

Schräder, Nicholas H. B.; Yuen, Wing Yan; Jonkman, Marcel F.

doi:10.2340/00015555-2827

Cited by 25 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pain in EB significantly impacts quality of life and day‐to‐day functioning . In addition to nociceptive pain associated with blistering and wounds, peripheral nerve damage objectified in RDEB, and postulated in JEB, adds plausibility to reported high pain scores in these EB types . Neuropathies limit the central role of opioids for EB pain as they may be less effective for this type of pain according to systematic analysis …”

Section: Discussionmentioning

confidence: 99%

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Pain and Itchmentioning

confidence: 99%

“…The burden of pain and itch was reported in seven studies [53,54,[57][58][59][60][61], 5 of which utilized patient-reported outcome measures (PROMs, Table 5) [53,[57][58][59][60]. Patients with RDEB reported high levels of pain and pruritus compared to patients with DDEB, epidermolysis bullosa simplex (EBS), and other skin diseases [53,[57][58][59][60]. In a US survey study, patients with RDEB (N = 32) ranked the top three most bothersome symptoms to be skin lesions and blisters (7/32 [23%]), itching (5/32 [16%]), and pain (5/32 [16%]) [61].…”

Section: Pain and Itchmentioning

confidence: 99%

“…The worst pain experienced over the previous 12 months also did not differ by patient-reported skin disease severity in this cohort. Patients with RDEB assessing their pain via the [60].…”

Section: Pain and Itchmentioning

confidence: 99%

“…Eighteen studies utilized 16 distinct PROMs (Table 5) [19,24,47,53,54,[57][58][59][60][61][67][68][69][70][71][72][73][74]. The most commonly used PROMs were the Quality of Life in Epidermolysis Bullosa survey (QOLEB) [54,59,61,[69][70][71], the Visual Analogue Scale (VAS) for pain or pruritus [58,59], and the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB) [68,72].…”

Section: Patient-reported Outcome Measures (Proms)mentioning

confidence: 99%

See 2 more Smart Citations

A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa

Tang¹,

Marinkovich²,

Lucas³

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background/objective Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic collagen disorder characterized by skin fragility leading to blistering, wounds, and scarring. There are currently no approved curative therapies. The objective of this manuscript is to provide a comprehensive literature review of the disease burden caused by RDEB. Methods A systematic literature review was conducted in MEDLINE and Embase in accordance with PRISMA guidelines. Observational and interventional studies on the economic, clinical, or humanistic burden of RDEB were included. Results Sixty-five studies were included in the review. Patients had considerable wound burden, with 60% reporting wounds covering more than 30% of their body. Increases in pain and itch were seen with larger wound size. Chronic wounds were larger and more painful than recurrent wounds. Commonly reported symptoms and complications included lesions and blistering, anemia, nail dystrophy and loss, milia, infections, musculoskeletal contractures, strictures or stenoses, constipation, malnutrition/nutritional problems, pseudosyndactyly, ocular manifestations, and dental caries. Many patients underwent esophageal dilation (29–74%; median dilations, 2–6) and gastrostomy tube placement (8–58%). In the severely affected population, risk of squamous cell carcinoma (SCC) was 76% and mortality from SCC reached 84% by age 40. Patients with RDEB experienced worsened quality of life (QOL), decreased functioning and social activities, and increased pain and itch when compared to other EB subtypes, other skin diseases, and the general population. Families of patients reported experiencing high rates of burden including financial burden (50–54%) and negative impact on private life (79%). Direct medical costs were high, though reported in few studies; annual payer-borne total medical costs in Ireland were $84,534 and annual patient-borne medical costs in Korea were $7392. Estimated annual US costs for wound dressings ranged from $4000 to $245,000. Patients spent considerable time changing dressings: often daily (13–54% of patients) with up to three hours per change (15–40%). Conclusion Patients with RDEB and their families/caregivers experience significant economic, humanistic, and clinical burden. Further research is needed to better understand the costs of disease, how the burden of disease changes over the patient lifetime and to better characterize QOL impact, and how RDEB compares with other chronic, debilitating disorders.

show abstract